MedTrace Logo

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

NCT03139513 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-01-22

No results posted yet for this study

Summary

This is a multicentre, ambispective (both retrospective and prospective), and non-interventional study conducted in France in adult participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib (Zelboraf®).

Conditions

Interventions

DRUG

Cobimetinib

Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.

DRUG

Vemurafenib

Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-27
Primary Completion
2018-08-22
Completion
2018-08-22
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139513 on ClinicalTrials.gov